What empiric antimicrobial therapy should be started for an adult patient with aerobic cultures showing moderate growth Enterococcus faecalis and heavy growth of Gram‑negative bacilli?

Empiric Antimicrobial Therapy for Polymicrobial Intra-abdominal Infection

Start piperacillin-tazobactam 3.375 g IV every 6 hours immediately as empiric therapy for this polymicrobial infection with Enterococcus faecalis and Gram-negative bacilli. This single agent provides comprehensive coverage for both pathogens and is the preferred first-line regimen based on established guidelines 1.

Rationale for Piperacillin-Tazobactam

The culture results reveal a polymicrobial infection requiring broad-spectrum coverage:

• Moderate growth Enterococcus faecalis (Gram-positive cocci in chains)
• Heavy growth Gram-negative bacilli (multiple strains)
• Normal skin flora (likely contaminant)
• Absence of PMNs (notable finding)

Piperacillin-tazobactam is specifically recommended by the Surgical Infection Society/IDSA guidelines as a β-lactam/β-lactamase inhibitor combination for complicated intra-abdominal infections 1. This agent uniquely covers:

• Enterococcus faecalis (intrinsically susceptible to ampicillin-class agents)
• Gram-negative bacilli including Pseudomonas aeruginosa
• Anaerobes (though none isolated here)

Why Enterococcal Coverage Matters Here

You must cover Enterococcus faecalis empirically in this scenario because:

1. Moderate growth from an intra-abdominal source indicates pathogenic significance, not colonization 1
2. The guidelines explicitly state that organisms recovered in "moderate or heavy concentrations from samples obtained from drainage" should be assumed significant 1
3. E. faecalis is ampicillin-susceptible in 82% of cases, making piperacillin-tazobactam an excellent empiric choice 2

The culture report's warning about cephalosporins, aminoglycosides, clindamycin, and TMP-SMX being ineffective against enterococci is critical—these agents would fail despite appearing active in vitro. This eliminates common empiric regimens like ceftriaxone + metronidazole or cefepime + metronidazole as monotherapy options.

Alternative Regimens (If Piperacillin-Tazobactam Unavailable or Contraindicated)

If β-lactam allergy or other contraindications exist:

Option 1: Carbapenem monotherapy

• Meropenem 1 g IV every 8 hours, OR
• Imipenem-cilastatin 500 mg IV every 6 hours
• These cover both E. faecalis and Gram-negatives 1

Option 2: Combination therapy for severe β-lactam allergy

• Ciprofloxacin 400 mg IV every 12 hours PLUS metronidazole 500 mg IV every 8 hours PLUS vancomycin 15-20 mg/kg IV every 8-12 hours
• The vancomycin specifically targets enterococci 1

Critical Pitfalls to Avoid

1. Do NOT use cephalosporins alone—they have zero clinical activity against enterococci despite in vitro susceptibility 1
2. Do NOT use aminoglycosides as monotherapy—same issue as cephalosporins for enterococci
3. Do NOT omit enterococcal coverage when E. faecalis grows in moderate/heavy amounts from intra-abdominal sources 1
4. Do NOT assume this is contamination—the absence of PMNs does not negate pathogenicity when organisms grow in moderate-to-heavy concentrations from normally sterile sites

When to Narrow Therapy

Once susceptibility data return:

• If E. faecalis is ampicillin-susceptible (likely): Consider narrowing to ampicillin alone if Gram-negatives are controlled or source-controlled 1, 2
• If Gram-negatives are susceptible to narrower agents: Tailor based on specific susceptibilities while maintaining enterococcal coverage 1
• Continue therapy until source control is achieved and clinical improvement documented 1

Special Considerations

The absence of PMNs on Gram stain is unusual but does not change management—the organism burden (moderate E. faecalis, heavy Gram-negatives) drives treatment decisions, not inflammatory cell counts 1. This may indicate:

• Early infection
• Immunosuppression
• Sampling from a walled-off collection

Duration of therapy: If adequate source control is achieved (drainage, surgical intervention), antibiotics can be discontinued within 24 hours for lower-risk patients with satisfactory clinical response 1. For persistent signs of infection or inadequate source control, continue pathogen-directed therapy based on cultures 1.

The polymicrobial nature with skin flora suggests possible contamination of that component, but the enterococci and Gram-negative bacilli in moderate-to-heavy growth represent true pathogens requiring treatment 1.